Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference
Emergent BioSolutions Gets Anthrax Vaccine Contract Modification Up to $22.3M
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Trading Information
- Previous Close Price
- $5.81
- Day Range
- $5.55–5.90
- 52-Week Range
- $4.36–14.06
- Bid/Ask
- $5.52 / $6.20
- Shares Outstanding
- 51.42M
- Market Cap
- $288.44M
- Volume/Avg
- 872,841 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 5.80
- Price/Sales
- 0.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 9.43%
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 900
Valuation
Metric | EBS |
|---|---|
Price/Earnings (Normalized) | 5.80 |
Price/Book Value | 0.92 |
Price/Sales | 0.47 |
Price/Cash Flow | 4.76 |
Price/Earnings
EBS
Financial Strength
Metric | EBS |
|---|---|
Quick Ratio | 2.08 |
Current Ratio | 4.58 |
Interest Coverage | −4.29 |
Quick Ratio
EBS
Profitability
Metric | EBS |
|---|---|
Return on Assets (Normalized) | 0.11% |
Return on Equity (Normalized) | 0.31% |
Return on Invested Capital (Normalized) | 3.40% |
Return on Assets
EBS
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|&?#!>q$! | LOCK|?#Y< | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|Vvkmwqw$ | LOCK|r&?f$ | $49B | |||
| Haleon PLC ADR HLN | LOCK|BJMlnqM | LOCK|#^ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|D^$#CM@B | LOCK|Z? | $34B | |||
| Viatris Inc VTRS | LOCK|&!sxj> | LOCK|<$ | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|fB> | LOCK|Ty | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|t?n@Qyr | LOCK|<Pk | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|gRFLB< | LOCK|!vN | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|^X^%&V& | LOCK|jlC> | $2B | |||
| Perrigo Co PLC PRGO | LOCK|W>zK@? | LOCK|KQB | $2B |